Michael A. Davies, MD, PhD, discusses the potential utility of ERK inhibitors in melanoma.
Michael A. Davies, MD, PhD
Advertisement
Articles by Michael A. Davies, MD, PhD
Michael A. Davies, MD, PhD, discusses the management of patients with melanoma during the COVID-19 pandemic.
Michael A. Davies, MD, PhD, discusses the potential role of novel BRAF inhibitors in treating patients with melanoma and brain metastases.
Michael A. Davies, MD, PhD, discusses the utility of retreatment with combination BRAF/MEK inhibitors in BRAF-mutant melanoma.
Michael A. Davies, MD, PhD, discusses factors to consider when selecting between combination regimens in BRAF-mutant melanoma.
Advertisement
Latest Updated Articles
Dr. Davies on Managing Melanoma During the COVID-19 PandemicPublished: April 28th 2021 | Updated:
Dr. Davies on the Potential Utility of ERK Inhibitors in MelanomaPublished: May 5th 2021 | Updated:
Dr. Davies on the Potential Role of Novel BRAF Inhibitors in Melanoma Brain MetastasesPublished: March 22nd 2021 | Updated:
Dr. Davies on the Utility of Retreatment With BRAF/MEK Inhibitors in BRAF-Mutant MelanomaPublished: February 24th 2021 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Dr Braunstein on the FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma
4
Meta-Analysis Characterizes Nivolumab/Ipilimumab Hyperprogression in Renal Medullary Carcinoma
5